The company has formed a “strategic partnership” with inVentiv Health , who does a lot of outsourcing for big Pharma, earlier this year, so perhaps some the sales and marketing slated for sales will be moving in this direction. Merck is not the only company investigating and pursuing this direction...
The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...
The costs of cancer treatment and associated drugs is rising as we all know. We are pouring money into R and D as fast as we can, and yes that does cost money, but insurers are making it hard to get insurance coverage and somewhere along the line you need to have a drug that is affordable as well...
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
What the top R and D managers from 4 big Pharma companies were talking about, yes they have a bit more of a cushion than Wall Street, but the failure rates and dollars invested don’t seem to be coming together too well either, from the Wall Street Health Blog. When you add it up, just these 4 were...
Interesting article with some good background information about drugs that are close to or are related to the "street drugs" as we know them. There are definitely a number of researchers who want to delve into this further, but with bad raps and being illegal in their "street drug"...
Posted to
The Medical Quack .... by Barbara Duck
on 09-11-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, FDA, DEA, R and D, street drugs
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
on 09-05-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing